6/5/2013

The FDA has granted priority review status to Bristol-Myers Squibb and AstraZeneca's biologics license application for metreleptin. The experimental drug is designed to treat metabolic disorders related to inherited or acquired lipodystrophy.

Full Story:
RTT News

Related Summaries